[go: up one dir, main page]

AR057812A1 - Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas - Google Patents

Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas

Info

Publication number
AR057812A1
AR057812A1 ARP060103990A ARP060103990A AR057812A1 AR 057812 A1 AR057812 A1 AR 057812A1 AR P060103990 A ARP060103990 A AR P060103990A AR P060103990 A ARP060103990 A AR P060103990A AR 057812 A1 AR057812 A1 AR 057812A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydroxy
fluor
alkoxy
alkyl
Prior art date
Application number
ARP060103990A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057812A1 publication Critical patent/AR057812A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Estos compuestos inhiben la L-CPT1 y pueden utilizarse como medicamentos. Procesos de obtencion de los mismos y composiciones farmacéuticas. Reivindicacion 1: Compuestos de la formula (1) en la que X es N o CR8; Y es N o CR9; A es - C(R10R11)C(R12R13)-, -C(R10R11)C(R12R13) C(R14R15), -C(R10R11)C(R12R13)C(R14R15)C(R16R17)-, -C(R10R11)C(R12R13)C(R14R15)C(R16R17)C(R18R19)- o -C(R10)=C(R11)-; R1, R2, R3, R4 y R5 con independencia entre sí son hidrogeno, halogeno, ciano, hidroxi, alquilo inferior, fluor-alquilo inferior, alcoxi inferior, fluor-alcoxi inferior, alquilo inferior-C(O), alquilo inferior-C(O)-NH, alquilo inferior-C(O)-N(alquilo inferior), alquilo inferior-S(O)2, NH2-S(O)2, NH2-S(O)2, N(H,alquilo inferior)S-(O)2 o N(alquilo inferior)2-S(O)2, NH2-C(O), N(H,alquilo inferior)-C(O), N(alquilo inferior)2-C(O) o alcoxi inferior-C(O), en los que alquilo inferior está opcionalmente sustituido con hidroxi, alcoxi inferior, NH2, N(H,alquilo inferior) o N(alquilo inferior)2; R6 es hidrogeno, halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior, hidroxi o hidroxi-alquilo inferior; R7 es hidrogeno, halogeno, hidroxi, ciano, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior o hidroxi-alquilo inferior; R8 es hidrogeno, halogeno, ciano, alquilo inferior, fluor-alquilo inferior, alcoxi inferior, fluor-alcoxi inferior, alquilo inferior-C(O), alquilo inferior-C(O)-NH, alquilo inferior-C(O)- N(alquilo inferior), alquilo inferior-S(O)2, NH2-S(O)2, N(H,alquilo inferior)-S(O)2, N(alquilo inferior)2-S(O)2, NH2-C(O), N(H,alquilo inferior)-C(O), N(alquilo inferior)2-C(O), alcoxi inferior-C(O), COOH, 1H-tetrazolilo, 4H-[1,2,4]oxadiazol-3-il-5- ona, 4H-[1,2,4]tiadiazol-3-il-5- ona, 4H-[1,2,4]oxadiazol-3-il-5-tiona, 3H-[1,2,3,5]oxatiadiazol-4-il2-oxido, SO3H, 3-hidroxi-isooxazolilo, 3-hidroxi-piran-4-on-ilo o P(O) (OCH2CH3)OH, en los que alquilo inferior está opcionalmente sustituido con hidroxi, NH2, N(H,alquilo) inferior o N(alquilo inferior)2 y en los que fluor-alquilo inferior está opcionalmente sustituido con hidroxi; R9 es hidrogeno, halogeno, hidroxi, ciano, alquilo inferior, alcoxi inferior, fluor- alquilo inferior, fluor- alcoxi inferior o hidroxi-alquilo inferior; R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 con independencia entre sí son hidrogeno, halogeno, hidroxi, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior, hidroxi- alquilo inferior o ciano; y las sales y ésteres farmacéuticamente aceptables de los mismos.
ARP060103990A 2005-09-15 2006-09-13 Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas AR057812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05108468 2005-09-15

Publications (1)

Publication Number Publication Date
AR057812A1 true AR057812A1 (es) 2007-12-19

Family

ID=37488076

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103990A AR057812A1 (es) 2005-09-15 2006-09-13 Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas

Country Status (13)

Country Link
US (1) US7713996B2 (es)
EP (1) EP1926711B1 (es)
JP (1) JP4843040B2 (es)
KR (1) KR101089878B1 (es)
CN (1) CN101263116B (es)
AR (1) AR057812A1 (es)
AU (1) AU2006290803B2 (es)
BR (1) BRPI0616246A2 (es)
CA (1) CA2621404C (es)
ES (1) ES2398111T3 (es)
IL (1) IL189663A (es)
TW (1) TW200745032A (es)
WO (1) WO2007031429A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
US7799933B2 (en) 2006-12-21 2010-09-21 Hoffman-La Roche Inc. Sulfonamide derivatives
KR100847448B1 (ko) * 2007-03-22 2008-07-21 한국화학연구원 3-아릴-5-알킬-1,2,4-옥사다이아졸 유도체, 그 제조방법 및이를 포함하는 비만 예방 또는 치료용 조성물
AU2008257693B2 (en) * 2007-06-01 2011-01-27 F. Hoffmann-La Roche Ag Piperidine-amide derivatives
WO2009002433A1 (en) * 2007-06-22 2008-12-31 Dara Biosciences, Inc. Compositions and methods for treating skin disorders
US20110230555A1 (en) * 2008-06-24 2011-09-22 David Middlemiss Enzyme Inhibitors and the Use Thereof
WO2010017827A1 (en) * 2008-08-14 2010-02-18 European Molecular Biology Laboratory 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
JP6242868B2 (ja) 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015131035A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
HK1253734A1 (zh) 2015-06-11 2019-06-28 The Regents Of The University Of Michigan 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
CA3002846A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof
KR20180070697A (ko) 2015-10-27 2018-06-26 머크 샤프 앤드 돔 코포레이션 Ror감마t 저해제로서의 치환된 인다졸 화합물 및 이의 용도
AU2016344118A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
CN106854172B (zh) * 2016-12-11 2019-04-19 山东轩德医药科技有限公司 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法
WO2018234807A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
GB2572526A (en) * 2017-06-22 2019-10-09 Curadev Pharma Ltd Heterocyclic small molecule modulators of human STING
WO2021226076A1 (en) * 2020-05-04 2021-11-11 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for detection of bacterial infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934307B1 (en) * 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
EP1926711B1 (en) 2012-11-07
CN101263116B (zh) 2011-12-07
KR20080046244A (ko) 2008-05-26
WO2007031429A1 (en) 2007-03-22
CA2621404A1 (en) 2007-03-22
CA2621404C (en) 2012-01-24
AU2006290803B2 (en) 2009-11-26
CN101263116A (zh) 2008-09-10
AU2006290803A1 (en) 2007-03-22
US20070060567A1 (en) 2007-03-15
BRPI0616246A2 (pt) 2011-06-14
IL189663A0 (en) 2008-06-05
US7713996B2 (en) 2010-05-11
IL189663A (en) 2012-03-29
JP2009507884A (ja) 2009-02-26
ES2398111T3 (es) 2013-03-13
JP4843040B2 (ja) 2011-12-21
EP1926711A1 (en) 2008-06-04
TW200745032A (en) 2007-12-16
KR101089878B1 (ko) 2011-12-05

Similar Documents

Publication Publication Date Title
AR057812A1 (es) Heterobiciclos nitrogenados con accion sobre l-cpt1. procesos de obtencion y composiciones farmaceuticas
AR059425A1 (es) Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
UY30440A1 (es) Nuevos compuestos
HN2011003014A (es) Neocleosidos uracilo espiro ocetano en fecha 16 de noviembre de 2011 se solicita por parte del titular de la invencion modificacion del titulo, ahora se denomina: espironucleosidos uraciclicos oxetanicos
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
PA8591701A1 (es) Derivados de pirrolopirimidina
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
CR10376A (es) Derivados de terfenil para el tratamiento de la enfermedad de alzheimer
ECSP034914A (es) "azaindoles"
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
AR031680A1 (es) Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
AR075050A1 (es) Dicianopiridinas alquilamino-sustituidas
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
AR063097A1 (es) Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
UY27979A1 (es) Indoles sustituidos en posición 2,4
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal